On Nov. 16, 2020, Bausch Health announced the results of new investigational in vitro data showing that two benzalkonium chloride preserved eye drops, LUMIFYﾮ redness reliever eye drops and BESIVANCEﾮ 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2.

In the study, researchers evaluated the in vitro antiviral activity of LUMIFY and BESIVANCE against SARS-CoV-2 using a Vero E-6 host-cell system. The activity of BAK against SARS-CoV-2 was not well understood.